The USPTO has announced the COVID-19 Prioritized Examination Pilot Program to incentivize prompt research into treatment of this pandemic. The program will benefit small and micro entities by allowing them to file for prioritized examination without the typical fees. To qualify for this program, the claims of the application must cover a product or process that is subject to FDA approval for use in the prevention and/or treatment of COVID-19. The USPTO aims to reach final disposition of applications to this program within six months, if the applicant responds promptly to USPTO communications. WHIPgroup attorneys have significant experience in products and processes subject to FDA approval, including medical devices and chemical compositions. We are ready and able to help you take advantage of this program.
By Christopher J. Stankus COVID-19 has brought numerous changes to the legal industry’s approach to working remotely. Some changes have been ordered by the courts, while others have been instituted by practitioners. Some of these [Read More…]
WHIPgroup secured a favorable decision by the Patent Trial and Appeal Board (PTAB), reversing all obviousness rejections of claims directed to a rotating electrical machine. In particular, WHIPgroup successfully argued that the prior art motor [Read More…]
On Thursday, May 21, 2020, the Southern District Court of California dismissed all claims brought by Hylete, Inc. against WHIPgroup clients Rob Orlando and Hybrid Athletics because, according to the Court, all Hylete’s claims were [Read More…]